Ex parte EDGREN et al. - Page 2

                  Appeal No.  1997-1160                                                                                    
                  Application No.  08/036,566                                                                              

                         Claim 24 is illustrative of the subject matter on appeal and is reproduced                        
                         24. A dosage form for administering an anti-Parkinson drug to a patient, wherein                  
                             the dosage form comprises:                                                                    
                             (a) a composition comprising 0.10 mg to 750 mg of an anti-Parkinson drug                      
                         and a pharmaceutically acceptable carrier for the anti-Parkinson drug selected                    
                         from the group consisting of hydroxypropylcellulose, hydroxypropylmethyl-cellulose                
                         and polyvinylpyrrolidone, which composition in the presence of fluid that contacts                
                         the dosage form provides a dispensable anti-Parkinson therapeutic formulation;                    
                         and wherein the dosage form:                                                                      
                             (b)  provides the anti-Parkinson drug substantially-free of adverse                           
                         effects for administration in a rate-controlled metered dose per unit time over                   
                         24 hours.                                                                                         
                             Claim 26 is directed to a method of management of paralysis agitans by                        
                  administering a drug composition that essentially parallels claim 24.  Claims 25 and 27                  
                  depend from claims 24 and 26 respectively and add the limitation of a particular anti-                   
                  Parkinson drug selected from a Markush grouping which includes, inter alia, levodopa,                    
                  carbidopa, levodopa-carbidopa and trihexyphenidyl.                                                       
                         The reference relied upon by the examiner is:                                                     
                  Physicians’ Desk Reference (PDR), 43rd Edition, pp. 1110-111, 1390-391 (1989)                            


Page:  Previous  1  2  3  4  5  6  Next 

Last modified: November 3, 2007